Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Viatar CTC Solutions Inc. (OTC: VRTT).

Full DD Report for VRTT

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A0.35N/AN/A0
2018-12-13N/A0.35N/AN/A0
2018-12-12N/A0.35N/AN/A0
2018-12-11N/A0.35N/AN/A0
2018-12-10N/A0.35N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-066,0009,50063.1579Short
2018-06-051,5001,500100.0000Short
2018-03-125,0005,000100.0000Short
2018-03-062,0002,000100.0000Short
2018-01-081,5005,00030.0000Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VRTT.


About Viatar CTC Solutions Inc. (OTC: VRTT)

Logo for Viatar CTC Solutions Inc. (OTC: VRTT)

Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The company s lead product, the Viatar Therapeutic Oncopheresis System, removes circulating tumor cells from whole blood using label free cross flow filtration. Pending regulatory approval targeted for , it will be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate and gastric cancers. This proprietary technology also powers the company s liquid biopsy products, which are collection systems for use by genetic testing companies, researchers and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives.

 

 

 

Current Management

  • Ilan Reich / President, CFO
    • Ilan Reich has more than years of CEO experience in medical device and instrumentation companies and has served as our Chairman, President and CEO since he founded the Company in . From until , Mr. Reich served as a corporate advisor on a variety of projects, including for RainDance Technologies from to , Warburg Pincus , and Gabelli Partners from to . From , he served in various senior executive positions at Inamed Corporation, including President, CoCEO and director. Inamed is a medical device manufacturer of implants for plastic surgery, aesthetics and obesity. Mr. Reich began his career as a corporate and securities lawyer and spent approximately years advising on more than public company M amp A transactions. Mr. Reich received his J.D. from Columbia University School of Law in where he was an editor of the Columbia Law Review and B.A. in political science from Columbia College in . In , Mr. Reich pleaded guilty to two counts of mail and securities fraud arising from his tipping confidential information to a third party at two intervals during to regarding merger and acquisition transactions in which Mr. Reich s law firm was involved. Mr. Reich did not receive any compensation for providing that information. He paid a fine to the US Treasury, served a prison term, was disbarred as an attorney in New York, and consented to an injunction on future violations. In , Mr. Reich was readmitted to the New York bar. Mr. Reich s career was the subject of a profile in Fortune Magazine in June .
  • Stephen Keaney / VP, R amp D
    • Stephen Keaney has over years of engineering, product development and regulatory experience in bringing medical devices from the design stage to market at a variety of major medical device companies. Mr. Keaney has been an employee of the Company since with the title of Director of Research and Development and was appointed Vice President of Research and Development in . Prior to this, he served as a project manager for Volcano Corporation from to , where he lead a cross functional team to develop a deflectable forward looking intravascular ultrasound catheter with radiofrequency ablation capabilities. During to , Mr. Keaney worked as an R amp D Manager at Boston Scientific Corporation. From to , Mr. Keaney was a Director in Foster Corporation, where he managed a team engineers to provide engineering consulting services to medical and industrial clients. Before , Mr. Keaney served as project manager/engineer for more than years with CardiFocus, Inc. from to , Implemed, Inc. from to , and C.R. Bard, Inc. from to . Mr. Stephen received his B.S. in Plastics Engineering from the University of Massachusetts, Lowell and he has completed all course requirements to receive his D. Eng. in engineering from the University of Massachusetts, Lowell.
  • Ilan Reich / Director
    • Ilan Reich has more than years of CEO experience in medical device and instrumentation companies and has served as our Chairman, President and CEO since he founded the Company in . From until , Mr. Reich served as a corporate advisor on a variety of projects, including for RainDance Technologies from to , Warburg Pincus , and Gabelli Partners from to . From , he served in various senior executive positions at Inamed Corporation, including President, CoCEO and director. Inamed is a medical device manufacturer of implants for plastic surgery, aesthetics and obesity. Mr. Reich began his career as a corporate and securities lawyer and spent approximately years advising on more than public company M amp A transactions. Mr. Reich received his J.D. from Columbia University School of Law in where he was an editor of the Columbia Law Review and B.A. in political science from Columbia College in . In , Mr. Reich pleaded guilty to two counts of mail and securities fraud arising from his tipping confidential information to a third party at two intervals during to regarding merger and acquisition transactions in which Mr. Reich s law firm was involved. Mr. Reich did not receive any compensation for providing that information. He paid a fine to the US Treasury, served a prison term, was disbarred as an attorney in New York, and consented to an injunction on future violations. In , Mr. Reich was readmitted to the New York bar. Mr. Reich s career was the subject of a profile in Fortune Magazine in June .

Current Share Structure

  • Market Cap: $9,747,713 - 03/16/2018
  • Authorized: 100,000,000 - 09/30/2016
  • Issue and Outstanding: 19,495,426 - 11/14/2016
  • Float: 9,404,825 - 05/15/2015

 



Daily Technical Chart for (OTC: VRTT)

Daily Technical Chart for (OTC: VRTT)


Stay tuned for daily updates and more on (OTC: VRTT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: VRTT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VRTT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VRTT and does not buy, sell, or trade any shares of VRTT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/